[1]CurrentPatentAssignee:NINGBOSMARTPHARMACEUTICAL-CN110204540,2019,ALocationinpatent:Paragraph0027;0033;0036-0037
[2]CurrentPatentAssignee:SUMITOMOCHEMICALCOMPANYLIMITED;SumitomoChemical(w/oDongwooFine-Chem)-US6433168,2002,B1
[3]CurrentPatentAssignee:SUMITOMOCHEMICALCOMPANYLIMITED;SumitomoChemical(w/oDongwooFine-Chem)-US6433168,2002,B1
[1]CurrentPatentAssignee:RECHSETDAPPLICSCIENTSOGE;SOGERAS-US3987042,1976,A
[1]Locationinpatent:experimentalpartGonnot,Vanessa;Nicolas,Marc;Mioskowski,Charles;Baati,Rachid[ChemicalandPharmaceuticalBulletin,2009,vol.57,#11,p.1300-1302]
[2]CurrentPatentAssignee:PIERREFABREPARCIPATIONS-US2010/105897,2010,A1Locationinpatent:Page/Pagecolumn3
Title: Gonnot V, et al. Expedient synthesis of mequitazine an antihistaminic drug by palladium catalyzed allylic alkylation of sodium phenothiazinate. Chem Pharm Bull (Tokyo). 2009 Nov;57(11):1300-2.
Title: El-Nakeeb MA, et a. In vitro antibacterial activity of some antihistaminics belonging to different groups against multi-drug resistant clinical isolates. Braz J Microbiol. 2011 Jul;42(3):980-91.
Title: Martinez-Mir I, et al. Antihistaminic and anticholinergic activities of mequitazine in comparison with clemizole. J Pharm Pharmacol. 1988 Sep;40(9):655-6.
Title: Satake N, et al. Possible mechanisms of vasoinhibitory effects of mequitazine, an antiallergic agent, on the contractions of isolated rat aorta induced by K+, phenylephrine, 5-hydroxytryptamine, and Ca2+. J Cardiovasc Pharmacol. 1994 Apr;23(4):669-73.
